Candel Therapeutics Future Growth
Future criteria checks 3/6
Candel Therapeutics is forecast to grow earnings and revenue by 62.5% and 73.7% per annum respectively. EPS is expected to grow by 60.9% per annum. Return on equity is forecast to be -74.7% in 3 years.
Key information
62.5%
Earnings growth rate
60.90%
EPS growth rate
| Biotechs earnings growth | 25.5% |
| Revenue growth rate | 73.7% |
| Future return on equity | -74.70% |
| Analyst coverage | Low |
| Last updated | 21 Aug 2025 |
Recent future growth updates
Recent updates
Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
May 27Candel Therapeutics: Entering Its Pivotal Year
Feb 20Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Dec 11Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 69 | -9 | 3 | -33 | 5 |
| 12/31/2026 | N/A | -54 | -44 | -66 | 5 |
| 12/31/2025 | N/A | -19 | -46 | -58 | 5 |
| 6/30/2025 | N/A | -22 | -30 | -30 | N/A |
| 3/31/2025 | N/A | -40 | -27 | -27 | N/A |
| 12/31/2024 | N/A | -55 | -27 | -27 | N/A |
| 9/30/2024 | N/A | -52 | -29 | -29 | N/A |
| 6/30/2024 | N/A | -50 | -31 | -31 | N/A |
| 3/31/2024 | N/A | -37 | -32 | -32 | N/A |
| 12/31/2023 | N/A | -38 | -35 | -34 | N/A |
| 9/30/2023 | 0 | -32 | -34 | -34 | N/A |
| 6/30/2023 | 0 | -32 | -35 | -34 | N/A |
| 3/31/2023 | 0 | -27 | -35 | -34 | N/A |
| 12/31/2022 | 0 | -19 | -33 | -31 | N/A |
| 9/30/2022 | 0 | -12 | -31 | -30 | N/A |
| 6/30/2022 | 0 | -20 | -29 | -27 | N/A |
| 3/31/2022 | 0 | -33 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -36 | -24 | -22 | N/A |
| 9/30/2021 | 0 | -48 | -22 | -20 | N/A |
| 6/30/2021 | 0 | -35 | -17 | -15 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -12 | N/A |
| 12/31/2020 | 0 | -18 | -11 | -9 | N/A |
| 12/31/2019 | 0 | -8 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CADL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).
Earnings vs Market: CADL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CADL is expected to become profitable in the next 3 years.
Revenue vs Market: CADL is forecast to have no revenue next year.
High Growth Revenue: CADL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CADL is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/31 00:02 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Candel Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |